Neumedicines to Present at the 2011 Biotech Showcase™ Tuesday, January 11, 2011

Share Article

Neumedicines Inc. ("Neumedicines" or the "Company"), an early-stage biotechnology company headquartered in Pasadena, California, today announced that the Company will present at the 2011 Biotech Showcase this afternoon. The event will be held in San Francisco, CA.

The 2011 Biotech Showcase™ will be held on the 4th Floor of the Parc 55 Wyndham Hotel in San Francisco, CA. The Company is scheduled to make a presentation from 2:45-3:00 p.m. today, January 11, 2011 and will be available to meet with investors throughout the conference.

"We look forward to the opportunity to showcase Neumedicines for investors, industry experts and those from the scientific community at today’s event," said Dr. Lena Basile, the Company’s President and CEO. "We are proud of the progress that Neumedicines is experiencing at present and the future opportunities that are open to Neumedicines in the expanding hematology/oncology market."

About Neumedicines Inc.
Neumedicines, Inc. was founded in 2003 as a start-up company from the University of Southern California and is engaged in research and development of both prophylactics and therapeutics based on Interleukin-12 (IL-12) (HemaMax™) for the mitigation and reversal of myeloablative and myelosuppressive effects on the human hematopoietic system. In animal tumor models, HemaMax™ has been shown to be effective in restoring hematopoiesis following either radiation or chemotherapy, while providing concomitant anti-tumor effects over and above the primary therapy. A range of clinical applications for HemaMax™ is being pursued in the area of hematology/oncology. Neumedicines is also developing HSS1, a novel secreted protein with demonstrated anti-angiogenic effects and anti-tumor effects in glioma. For more information, please visit: http://www.neumedicines.com.

About HemaMax™
HemaMax™ is recombinant human interleukin-12 (rhuIL-12). Neumedicines is applying the previously unexplored hematological properties of IL-12 in the fields of hematology/oncology. Neumedicines has demonstrated in preclinical study the potent survival effects of single, low dose IL-12 on hematopoietic recovery following lethal radiation. HemaMax™ is a therapeutic that can be administered in very low, nanogram doses to achieve potent radiomitigation effects. Neumedicines has to date demonstrated that HemaMax™ can increase survival in mice and non-human primates treated with HemaMax™ in single, low doses 24 hours after lethal radiation exposure.

About Biotech Showcase™ 2011
Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives during the course of the world's largest annual healthcare investor conference. In its third year, Biotech Showcase moves to Parc 55 Wyndham San Francisco – Union Square and will expand to three full days. The program will include lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Richard Leon
Visit website